ArticleArchives of internal medicine research2026
Neuroinflammation and Mental Health in Multiple Sclerosis and Autoimmune Encephalitis: Bridging Biological Mechanisms and Psychosocial Factors.
Article in Archives of internal medicine research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Timely Surgical Approaches for Pediatric Epilepsy Resistant to Medication.Journal of surgery and research · 2026Article
- Stiff Person Syndrome: Bridging Neuroimmunology and Rehabilitation for Improved Patient Outcomes.Archives of internal medicine research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Autoimmune neuroinflammatory diseases, including multiple sclerosis (MS) and autoimmune encephalitis (AE), are characterized by dysregulated immune activity within the central nervous system that leads to both neurological and psychiatric symptoms. While MS is typically a chronic condition indicated by demyelination and progressive neurodegeneration, AE often presents more acutely through antibody-mediated disruption of synaptic function. Despite differences in disease course and mechanisms, both conditions highlight the significant impact of immune-mediated processes on cognition, mood, and behavior. Current treatment options primarily focus on reducing inflammation and controlling disease activity through immunomodulatory or immunosuppressive therapies. Although these approaches have improved neurological outcomes, many patients continue to experience persistent cognitive impairment and psychiatric symptoms, including depression, anxiety, and executive dysfunction. These symptoms are increasingly recognized as core features of disease rather than secondary symptoms. New research suggests that immune system activity works together with brain network changes and chronic stress to shape mental and neurological symptoms. However, these areas are often overlooked in clinical care and understudied in research. Future directions should prioritize integrating cognitive and psychiatric outcomes into clinical trials, developing biomarkers that link immune activity to neuropsychiatric symptoms, and implementing multidisciplinary treatment approaches. A more comprehensive understanding of both biological and psychosocial contributors is essential for improving long-term patient outcomes and quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.